The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index; 14 of the 40 sources its claims cite were checked for support.
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Open accessAbstract
BACKGROUND: Daratumumab showed promising efficacy alone and with lenalidomide and dexamethasone in a phase 1-2 study involving patients with relapsed or refractory multiple myeloma. METHODS: In this phase 3 trial, we randomly assigned 569 patients with multiple myeloma who had received one or more previous lines of therapy to receive lenalidomide and dexamethasone either alone (control group) or in combination with daratumumab (daratumumab group). The primary end point was progression-free survival. RESULTS: white cells), as compared with 4.6% of those in the control group (P<0.001); results below the threshold for minimal residual disease were associated with improved outcomes. The most common adverse events of grade 3 or 4 during treatment were neutropenia (in 51.9% of the patients in the daratumumab group vs. 37.0% of those in the control group), thrombocytopenia (in 12.7% vs. 13.5%), and anemia (in 12.4% vs. 19.6%). Daratumumab-associated infusion-related reactions occurred in 47.7% of the patients and were mostly of grade 1 or 2. CONCLUSIONS: The addition of daratumumab to lenalidomide and dexamethasone significantly lengthened progression-free survival among patients with relapsed or refractory multiple myeloma. Daratumumab was associated with infusion-related reactions and a higher rate of neutropenia than the control therapy. (Funded by Janssen Research and Development; POLLUX ClinicalTrials.gov number, NCT02076009 .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
14 of 40 cited sources checked · 9 supported · 0 flagged · accuracy not yet measured
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“However, this category of minimal residual disease status has not been examined to date in patients with relapsed or refractory multiple myeloma, in part because of limited availability of data showing a correlation between depth of response and survival outcomes in patients at this stage of the disease.7”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Abstract
What the sources say
- Partly supportedcites [7] sourceExperimental — accuracy not yet measured
The “Relapsed and/or refractory” section (page unavailable) says data linking depth of response to outcomes are limited, supporting the citing sentence’s rationale. The “Redefining CR” section discusses minimal residual disease (MRD) studies in newly diagnosed patients, but does not state that MRD status had never been examined in relapsed or refractory patients. The relapsed-setting section’s “MR” means minimal response, not minimal residual disease. (LLM, conf=0.78)
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“As in our trial (POLLUX), the addition of daratumumab to a standard-of-care regimen of bortezomib and dexamethasone in the CASTOR trial was associated with a significantly lower risk of disease progression or death.18”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Discussion
What the sources say
- Supportedcites [18] source
The Trial Treatments section (p. 3) confirms that CASTOR compared daratumumab plus bortezomib and dexamethasone with bortezomib and dexamethasone alone. The Discussion (p. 11) reports significantly longer progression-free survival and a 61.4% lower risk of disease progression or death in the daratumumab group. (LLM, conf=0.94)
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passes- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Daratumumab with lenalidomide and dexamethasone was associated with clinically manageable adverse events that were consistent with the known toxic effects of lenalidomide and dexamethasone 27,28,30,31 and of daratumumab.9,10”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Patients who have very good partial responses
What the sources say
- Not checked — no full text of the sourcecites [27] source
- Supportedcites [28] source
The Safety section identifies thrombocytopenia, gastrointestinal events, and rash as adverse events observed with lenalidomide-dexamethasone, and describes management of gastrointestinal events with supportive therapy and dose adjustment. This supports the part of the sentence attributed to this paper: the known toxic effects of lenalidomide-dexamethasone. The daratumumab-specific part has separate citations and is not attributed to this source. (LLM, conf=0.90)
- Supportedcites [30] source
This citation is attached to the known toxic effects of lenalidomide and dexamethasone, not to the daratumumab-specific part of the sentence. The Randomization and Study Treatment section identifies a lenalidomide–dexamethasone control group, and the Safety section and Table 3 report its adverse events. The paper does not assess the daratumumab combination. (LLM, conf=0.84)
- Not checked — no full text of the sourcecites [31] source
- Not checked — no full text of the sourcecites [9] source
- Supportedcites [10] source
This source is cited for the known toxic effects of daratumumab, not for the safety of the three-drug combination. The Safety section (p. 5) reports that most adverse events with daratumumab were grade 1 or 2, and the Discussion (p. 11) describes an acceptable safety profile and mostly mild infusion-related reactions. (LLM, conf=0.89)
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Similar results were observed in the intentionto-treat population (Table S3 in the Supplementary Appendix).”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Efficacy
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Consistent with the higher rates of deeper responses in the daratumumab group, the rate of results below the threshold for minimal residual disease was significantly higher in the daratumumab group than in the control group (by 3 to 5 times) at all evaluated thresholds (1 tumor cell per 10 4 , 10 5 , and 10 6 white cells) (Fig. S4 in the Supplementary Appendix).”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Efficacy
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“At the interim analysis, a total of 75 deaths had been observed (30 patients in the daratumumab group and 45 in the control group) (Table S4 in the Supplementary Appendix).”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Efficacy
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A significantly higher rate of overall response was observed in the daratumumab group than in the control group (92.9% vs. 76.4%,P<0.001), as was a higher rate of complete response or better (43.1% vs. 19.2%,P<0.001).”
- Also stated in: § Efficacy · plain
“the rate of complete response or better (43.1% vs. 19.2%,P<0.001).”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Also stated in: § Efficacy · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Progression-free survival was similarly prolonged in the daratumumab group among patients who had previous exposure to lenalidomide and those who had no previous exposure, as compared with the control group (Fig. S3 in the Supplementary Appendix).”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Efficacy
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The median progression-free survival was not reached (95% CI, could not be estimated) in the daratumumab group, as compared with 18.4 months (95% CI, 13.9 to could not be estimated) in the control group.”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Efficacy
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Among patients with a partial response or better, the rate of progression-free survival at 12 months was 87.8% (95% CI, 83.1 to 91.3) in the daratumumab group versus 73.6% (95% CI, 67.0 to 79.1) in the control group.”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Efficacy
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Daratumumab, a human IgGκ monoclonal antibody that targets CD38, 8 has shown substantial single-agent efficacy and a manageable safety profile in phase 1-2 studies involving patients with heavily pretreated relapsed or refractory multiple myeloma, with reported overall response rates of 29% and 36%.9,10”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Abstract
What the sources say
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Daratumumab, a human IgGκ monoclonal antibody that targets CD38, 8 has shown substantial single-agent efficacy and a manageable safety profile in phase 1-2 studies involving patients with heavily pretreated relapsed or refractory multiple myeloma, with reported overall response rates of 29% and 36%.9,10”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Abstract
What the sources say
- Supportedcites [8] source
The Ab generation section states that all antibodies described, including daratumumab, were human IgG1, κ antibodies. The Discussion identifies daratumumab as a human IgG1 antibody that binds CD38. The later phase 1–2 efficacy claims carry separate citations and are not attributed to this source. (LLM, conf=0.94)
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The primary end point was progression-free survival, with progression determined with the use of a validated computer algorithm that combined laboratory results (e.g., M-protein level) and applicable imaging and generated the outcome according to IMWG criteria (see the Supplementary Appendix).20,21 This algorithm previously showed very strong concordance with independent reviews in a phase 2 study”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > End Points and Assessments
What the sources say
- Not checked — no full text of the sourcecites [20] source
- Partly supportedcites [21] sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 1 unverifiable. Expand the claim to see per-atom verdicts.
- Not checked — no full text of the sourcecites [9] source
Load-bearingStrength:boosted· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
Every source the paper cites for this claim was checked and supports it.
In the paper
“A phase 3 trial of bortezomib and dexamethasone, with or without daratumumab, met its primary end point at the interim analysis and showed a significantly higher rate of progression-free survival, with a 61% lower risk of progression or death in the daratumumab group than in the control group.18”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Abstract
What the sources say
- Supportedcites [18] source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“After the implementation of guidelines from other studies of daratumumab regarding the management of infusion-related reactions, infusion-related reactions were consistent with daratumumab monotherapy 9,10 and combination therapy, 18,19,32 were mostly of grade 1 or 2, and usually occurred during the first infusion.”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Patients who have very good partial responses
What the sources say
- Not checked — no full text of the sourcecites [9] source
- Supportedcites [10] source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
- Partly supportedcites [18] sourceExperimental — accuracy not yet measured
Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
- Not matchedcites [19] Plesner T, Blood
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Could not verifycites [32] Chari A, 2015, Blood sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 2 unverifiable. Expand the claim to see per-atom verdicts.
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Response was assessed according to the Uniform Criteria Consensus recommendations of the International Myeloma Working Group.20,21”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Efficacy
What the sources say
- Not checked — no full text of the sourcecites [20] source
- Supportedcites [21] source
The Response criteria section recommends using the IMWG uniform response criteria in clinical trials and says the panel endorsed their response definitions. The citation therefore supports the identification of the criteria used; it does not independently document how the citing study assessed response. (LLM, conf=0.93)
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Daratumumab interferes with laboratory-based bloodcompatibility tests, including indirect Coombs' test, because of binding to CD38 on red cells.26”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Table 3. Most Common Adverse Events during Treatment in the Safety Population.*
What the sources say
- Supportedcites [26] source
The Discussion says daratumumab interferes with blood compatibility testing because it binds directly to CD38 on red cells. The “DARA causes plasma panreactivity in vitro” section reports panreactivity at the antihuman globulin phase, supporting the reference to the indirect Coombs test. (LLM, conf=0.93)
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Daratumumab was associated with infusion-related reactions and a higher rate of neutropenia than the control therapy.”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Abstract
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Daratumumab-associated infusion-related reactions occurred in 47.7% of the patients and were mostly of grade 1 or 2.”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Abstract
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Similarly, in the time-toevent analysis of disease progression, a total of 148 events (in 44 patients [15.4%] in the daratumumab group vs. 104 [36.7%] in the control group) were observed (hazard ratio, 0.34; 95% CI, 0.23 to 0.48; P<0.001).”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Efficacy
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The percentage of patients with adverse events leading to the discontinuation of treatment was similar in the two groups: 6.7% in the daratumumab group and 7.8% in the control group.”
- Also stated in: § Patients who have very good partial responses · plain
“The rates of treatment discontinuation owing to adverse events were low and similar in the two groups.”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Table 3. Most Common Adverse Events during Treatment in the Safety Population.*
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Also stated in: § Patients who have very good partial responses · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The treatment effect of daratumumab was consistent regardless of previous exposure to lenalidomide (a limitation being the relatively small number of patients with previous exposure to lenalidomide) and across all subgroups, including patients 65 years of age or older, those with disease that was refractory to proteasome inhibitors or the most recent line of therapy, those with International Stag”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Discussion
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Although higher rates of neutropenia and infusion-related reactions (primarily during the first infusion) were observed with this combination than with lenalidomide and dexamethasone alone, these events did not result in higher rates of treatment discontinuation or death.”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Patients who have very good partial responses
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“After continued treatment, responses deepened, with a rate of complete response or better that was twice as high with daratumumab as with the backbone regimen alone.”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Discussion
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These reactions were mostly of grade 1 or 2; a total of 15 patients (5.3%) had grade 3 infusion reactions, and no patient had an event of grade 4 or 5.”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Table 3. Most Common Adverse Events during Treatment in the Safety Population.*
Strength:plain· not yet calibratedn = 15Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Overall response No. with response 261 211 -Rate -% (95% CI) 92.9 (89.2-95.6)76.4 (71.0-81.3)<0.001”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Efficacy
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Serious adverse events were reported in 48.8% of the patients in the daratumumab group and in 42.0% of those in the control group, among which pneumonia was the most common (in 8.1% of the patients in the daratumumab group and in 8.5% of those in the control group).”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Table 3. Most Common Adverse Events during Treatment in the Safety Population.*
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The rate of infection of grade 3 or 4 was also slightly higher in the daratumumab group than in the control group (28.3% and 22.8%, respectively); the most common infection of grade 3 or 4 was pneumonia, which occurred at similar rates in the two groups.”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Table 3. Most Common Adverse Events during Treatment in the Safety Population.*
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The most common adverse events leading to death were acute kidney injury (in 0.4% of the patients in the daratumumab group and in 1.1% in the control group), septic shock (in 1.1% and 0.4%, respectively), and pneumonia (in 0.7% in each group).”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Table 3. Most Common Adverse Events during Treatment in the Safety Population.*
Strength:plain· not yet calibratedn = 11Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“incidences of grade 3 or 4 diarrhea, fatigue, nausea, and dyspnea were slightly higher in the daratumumab group than in the control group.”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Table 3. Most Common Adverse Events during Treatment in the Safety Population.*
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Stringent complete response § 51 (18.1) 20 (7.2) -”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Efficacy
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The incidence of daratumumab infusionrelated reactions of any grade was 47.7%, with 92% of the reactions occurring during the first infusion.”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Table 3. Most Common Adverse Events during Treatment in the Safety Population.*
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The most common adverse events (in ≥1% of the patients in either group) that led to the discontinuation of treatment included pneumonia (in 1.1% of the patients in the daratumumab group and in 0.7% of those in the control group), pulmonary embolism (in 1.1% in the control group), and deterioration in general physical health (in 1.1% in the daratumumab group).”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Table 3. Most Common Adverse Events during Treatment in the Safety Population.*
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Despite higher rates of neutropenia in the daratumumab group, the rate of infection of grade 3 or 4 was only slightly higher in the daratumumab group than in the control group (28% vs. 23%).”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Patients who have very good partial responses
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“As in the CASTOR trial, 18 the addition of daratumumab to the backbone regimen in our trial resulted in a significantly higher rate of overall response, deeper responses, and longer duration of response.”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Discussion
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The most common infusion-related reactions were cough (in 8.5% of the patients), dyspnea (in 8.5%), and vomiting (in 5.7%) (Table S5 in the Supplementary Appendix).”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Table 3. Most Common Adverse Events during Treatment in the Safety Population.*
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“A phase 1-2 study of daratumumab, lena-lidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma showed that this combination provided therapeutic benefits, no dose-limiting toxic effects, and an 81% rate of overall response, including a 25% rate of stringent complete response”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Abstract
What the sources say
- Not matchedcites [19] Plesner T, Blood
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Not matched
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The group-sequential design had one planned interim analysis to evaluate the primary end point.”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Statistical Analysis
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“he incorporation of proteasome inhibitors and immunomodulatory drugs into the standard of care has improved outcomes in patients with multiple myeloma over the past 10 years, [1][2][3]”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Abstract
What the sources say
- Not matchedcites [1][2][3]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
- Not matched
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The trial was approved by the independent ethics committee or institutional review board at each site before the initiation of the trial.Patients provided written informed consent, and the trial was conducted in accordance with the principles of the Declaration of Helsinki and current International Conference on Harmonisation Good Clinical Practice guidelines.”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Trial Design
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“An independent data and safety monitoring committee was established to periodically review unblinded safety data.”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > End Points and Assessments
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“At 18 months, the rate of progression-free survival was 72%, and the rate of overall survival was 90%.19”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Abstract
What the sources say
- Not matchedcites [19] Plesner T, Blood
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
- Not matched
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The most common reasons for the discontinuation of treatment were progressive disease (in 14.1% of the patients in the daratumumab group vs. 34.2% of those in the control group) and adverse events (in 6.7% vs. 8.2%) (Fig. S2 in the Supplementary Appendix).”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Patients and Treatment
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“We calculated that approximately 560 patients with 295 events (disease progression or death) would be needed to provide the trial with 85% power to detect a 30% lower risk of disease progression or death (hazard ratio, 0.70), using a log-rank test, with an overall two-sided significance level of 0.05.”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Statistical Analysis
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“This suggests that results below the threshold for minimal residual disease also should be a treatment goal in the context of relapsed or refractory disease.”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Patients who have very good partial responses
Load-bearingStrength:hedged· not yet calibratedTests✓ Asserted: passes✗ Checkable: fails✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim. It may be too vague to check against evidence.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Figure 2. Prespecified Subgroup Analyses.”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Patients who have very good partial responses
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Shown are the results of the Kaplan-Meier analysis of progression-free survival among patients in the intention-totreat population, which included all patients who underwent randomization.”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Patients who have very good partial responses
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
The paper relies on this without support.
Relapse can occur even after standard complete remission in the context of first-line therapy.
“Relapse can occur even after standard complete remission in the context of first-line therapy, and studies are therefore evaluating deeper responses in a category termed “minimal residual disease-negative””
The paper relies on this without support.
The combination of lenalidomide and dexamethasone is an appropriate standard control regimen for patients with relapsed or refractory multiple myeloma who have received one or more previous lines of therapy.
“we randomly assigned 569 patients with multiple myeloma who had received one or more previous lines of therapy to receive lenalidomide and dexamethasone either alone (control group) or in combination with daratumumab (daratumumab group).”
The paper relies on this without support.
The open-label design does not bias the assessment of progression-free survival.
“In this randomized, open-label, multicenter, phase 3 trial, we assigned patients who had relapsed or refractory multiple myeloma and had received one or more lines of previous therapy to receive either daratumumab, lenalidomide, and dexamethasone (daratumumab group) or lenalidomide and dexamethasone (control group).”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The recently approved monoclonal antibody, daratumumab, which targets CD38 (a receptor highly expressed on myeloma cells), has become a favorite for later line induction regimens [35,36].”
From Epidemiology, Staging, and Management of Multiple Myeloma (2021) · cites this paper as [36]
Experimental — accuracy not yet measuredIn the citing paper
“Response rates to single-agent lenalidomide have consistently been surpassed by those achieved with doublet or triplet combinations, which has been taken as evidence for synergistic activity of this agent with other anti-myeloma agents48.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [48]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Control-group adverse-event discontinuation rates differ
MinorThe results give 8.2% of control-group patients as discontinuing treatment because of adverse events, but the safety section gives 7.8% for adverse events leading to treatment discontinuation. The text does not explain the difference.
“The most common reasons for the discontinuation of treatment were progressive disease (in 14.1% of the patients in the daratumumab group vs. 34.2% of those in the control group) and adverse events (in 6.7% vs. 8.2%)”
“The percentage of patients with adverse events leading to the discontinuation of treatment was similar in the two groups: 6.7% in the daratumumab group and 7.8% in the control group.”
Citations
Cites
Kumar, S., Paiva, B., Anderson, K. C., Durie, B., Landgren, O., Moreau, P., Munshi, N., Lonial, S., Bladé, J., Mateos, M.-V., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30206-6 · Cited by 3,061
Self-citationInternational uniform response criteria for multiple myeloma
Durie, B. G. M., Harousseau, J.-L., Miguel, J. S., Bladé, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404284 · Cited by 2,632
Self-citationDiscrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310
Improved survival in multiple myeloma and the impact of novel therapies
Kumar, S. K., Rajkumar, S. V., Dispenzieri, A. A., Lacy, M. Q., Hayman, S. R., Buadi, F. K., Zeldenrust, S. R., Dingli, D., Russell, S. J., Lust, J. A., et al. (2007) · Blood · doi:10.1182/blood-2007-10-116129 · Cited by 2,241
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
Palumbo, A., Chanan-Khan, A., Weisel, K., Nooka, A. K., Masszi, T., Beksac, M., Spicka, I., Hungria, V., Munder, M., Mateos, M. V., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606038 · Cited by 1,522
Self-citationLenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
Dimopoulos, M., Spencer, A., Attal, M., Prince, H. M., Harousseau, J.-L., Dmoszynska, A., Miguel, J. S., Hellmann, A., Facon, T., Foà, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070594 · Cited by 1,450
Self-citationKumar, S. K., Dispenzieri, A. A., Lacy, M. Q., Gertz, M. A., Buadi, F. K., Pandey, S., Kapoor, P., Dingli, D., Hayman, S. R., Leung, N., et al. (2013) · Leukemia · doi:10.1038/leu.2013.313 · Cited by 1,383
Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
Stewart, A. K., Rajkumar, S. V., Dimopoulos, M. A., Masszi, T., Špička, I., Oriol, A., Hájek, R., Rosiñol, L., Siegel, D. S., Mihaylov, G. G., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411321 · Cited by 1,332
Self-citationElotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
Lonial, S., Dimopoulos, M., Palumbo, A., White, D., Grosicki, S., Spicka, I., Walter-Croneck, A., Moreau, P., Mateos, M.-V., Magen, H., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1505654 · Cited by 1,322
Self-citationTargeting CD38 with Daratumumab Monotherapy in Multiple Myeloma
Lokhorst, H. M., Plesner, T., Laubach, J. P., Nahi, H., Gimsing, P., Hansson, M., Minnema, M. C., Lassen, U., Krejcik, J., Palumbo, A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1506348 · Cited by 1,117
Self-citation
Flagged first, then by citations
Research works printed but not linked: 2
- Krejcik J, Blood
- Plesner T, Blood
Cited by
Sorted by citations
Items 1,001–1,100 of 1,433
Dicato, M. A. (2018) · Springer eBooks · doi:10.1007/978-3-319-70253-7_10 · Cited by 4
Quantification of serum daratumumab in multiple myeloma patients by LC-MS/MS, comparison with ELISA
Li, W., Tian, Z., Xiong, Y., et al. (2024) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2024.116627 · Cited by 3
Ranganathan, S., & Prasad, V. K. (2025) · Journal of Cancer Policy · doi:10.1016/j.jcpo.2025.100588 · Cited by 3
CAR T-cells in multiple myeloma: the race to the start line
Bazarbachi, A. H., Bhutani, D., Hughes, M. S., Lentzsch, S., Mapara, M. Y., Muranski, P. J., Reshef, R., Wangjam, T., & Chakraborty, R. (2025) · Bone Marrow Transplantation · doi:10.1038/s41409-025-02787-9 · Cited by 3
Beksaç, M., Seval, G. C., Koyun, D., Topçuoğlu, P., Yüksel, M. K., Gürman, G., & İlhan, O. (2022) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2022.12.007 · Cited by 3
LeBlanc, R., Mian, H., Reece, D., Su, J.-D., Masih-Khan, E., Chu, M. P., Jimenez-Zepeda, V., Sebag, M., Song, K., Louzada, M., et al. (2023) · European Journal of Haematology · doi:10.1111/ejh.14082 · Cited by 2
Self-citationDaratumumab Treatment for “Truly Frail” Elderly Myeloma Patients
Horigome, Y., Suzuki, K., & Suzuki, T. (2024) · Life · doi:10.3390/life14030389 · Cited by 3
“…regimens early, as demonstrated in trials such as the MAIA trial [5,6] and POLLUX trial [7–10]. is suggested that for elderly MM patients, it is important to introduce highly effective treatment regimens early, as demonstrated in trials such as the MAIA trial [5,6] and POLLUX trial [7–10].”
BackgroundSelf-citationThromboprophylaxis in multiple myeloma: a case-based review with practical guidelines
Charalampous, C. M., Shah, D., Kumar, S. K., & Chakraborty, R. (2024) · Annals of Hematology · doi:10.1007/s00277-024-05733-9 · Cited by 3
“Low VTE rates are also seen with the lenalidomide and dexametha - sone combination, with an estimated risk of 3.9% in RRMM patients [ 66].”
InfluentialResponse to daratumumab-retreatment in patients with multiple myeloma
Souren, L., Ihorst, G., Greil, C., Engelhardt, M. M., & Wäsch, R. (2024) · Annals of Hematology · doi:10.1007/s00277-024-05991-7 · Cited by 3
“Rd) or CASTOR, was overall more favorable with less low-grade AEs, but the occurrence of AEs ≥ grade 3 was comparable to our study [28, 29].”
Mikulski, D., Kędzior, M. K., Mirocha, G., Jerzmanowska, K., Witas, Ż., Woźniak, Ł., Pawlak, M., Kościelny, K., Kośny, M., Robak, P. J., et al. (2024) · Cancers · doi:10.3390/cancers16213709 · Cited by 6
Bai, H., Zhang, C., Zhao, A., Tang, W., & Zhang, L. (2025) · Therapeutic Advances in Hematology · doi:10.1177/20406207251319593 · Cited by 3
“3,43 Previous studies have documented that daratumumab can significantly improve the rapidity and depth of hematologic responses in MM, 15,18,44,45 which suggests the potential of the anti-CD38 monoclonal antibody to promote the clearance of FLCs and represents a promising tool for the therapy of…”
Wu, W., Tang, F., Wang, Y., Yang, W., Zhao, Z., Gao, Y., & Dong, H. (2025) · Health Economics Review · doi:10.1186/s13561-025-00611-0 · Cited by 4
“This group encompasses five therapies [6, 8, 11, 30–32]: Treatments in the carfilzomib group are appropriate for first/second-relapse MM patients who exhibit sensitivity to carfilzomib.”
Developments in the Field of Myeloma in the Last Decade
Saikia, T. K. (2017) · Indian Journal of Hematology and Blood Transfusion · doi:10.1007/s12288-017-0777-0 · Cited by 3
Immunotherapy in Multiple Myeloma
Gleason, C. L., & Catamero, D. (2017) · Seminars in Oncology Nursing · doi:10.1016/j.soncn.2017.05.011 · Cited by 3
“The most common grade 3/4 AEs were thrombocytopenia and pneumonia in the singleagent DARA trial on the dose-expansion cohort, and anemia and thrombocytopenia in the SIRIUS trial, with hematologic issues in the combination trial with lenalidomide/dexamethasone.(22,24,27,29) Pre-medication with a corticosteroid, acetami…”
BackgroundFunding Innovation Thanks to Anti-TNF-α Biosimilars Uptake: The Economic Impact in Italy
Povero, M., & Pradelli, L. (2020) · Farmeconomia Health economics and therapeutic pathways · doi:10.7175/fe.v21i1.1449 · Cited by 3
Evidence-based supportive care in multiple myeloma
Qureshi, A., Tariq, M. J., Shah, Z., et al. (2020) · Journal of Community Hospital Internal Medicine Perspectives · doi:10.1080/20009666.2020.1771124 · Cited by 3
Consenso Mexicano de Mieloma Múltiple
de la Peña-Celaya, J. A., Aguilar-Luévano, J., Alcivar-Cedeño, L. M., Álvarez-Vera, J. L., Anaya-Cuéllar, I., Añorve-Hernández, É., Arana-Luna, L. L., Arteaga-Ortíz, L., Baez-Islas, P. E., Banda-García, L. I., et al. (2020) · Gaceta Médica de México · doi:10.24875/gmm.m20000393 · Cited by 3
Carfilzomib in Combination with Daratumumab in the Management of Relapsed Multiple Myeloma
Touzeau, C., Antier, C., & Moreau, P. (2020) · Future Oncology · doi:10.2217/fon-2020-0907 · Cited by 3
Self-citationFlow cytometric myeloma measurable residual disease testing in the era of targeted therapies
Ng, D. P. (2021) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.13587 · Cited by 4
Chim, C. S., Kumar, S. K., Wong, V. K. C., Ngai, C., & Kwong, Y. (2021) · Hematology · doi:10.1080/16078454.2021.1965737 · Cited by 3
“grade 3⁄4 neutropenia remained common with a frequency comparable to that observed in Pollux [4].”
BackgroundResultInfluentialMatsue, K., Sunami, K., Matsumoto, M., Kuroda, J., Sugiura, I., Iwasaki, H., Chung, W., Kuwayama, S., Nishio, M., Lee, K., et al. (2022) · International Journal of Hematology · doi:10.1007/s12185-022-03338-4 · Cited by 3
Fucci, L., Gensini, L., Coppetelli, U., et al. (2022) · Leukemia Research Reports · doi:10.1016/j.lrr.2022.100330 · Cited by 3
Harnessing the T Cell to Treat Multiple Myeloma: Dawn of a New Therapeutic Paradigm
Keller, A. L., Sherbenou, D. W., Forsberg, P. A., & Mark, T. M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.925818 · Cited by 3
Case Report: Invasive Fungal Infection and Daratumumab: A Case Series and Review of Literature
Farina, F., Ferla, V., Marktel, S., Clerici, D., Mastaglio, S., Perini, T., Oltolini, C., Greco, R., Aletti, F., Assanelli, A. A., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.867301 · Cited by 3
“3% respectively with a rate of grade 3-4 pneumonia of 9% (6, 7).”
BackgroundStakiw, J., Kodad, S. G., LeBlanc, R., Sébag, M., Hay, A. E., Kukreti, V., Côté, J. A., Camacho, F., Fu, M., Gul, E., et al. (2023) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2023.03.006 · Cited by 3
Self-citationLü, W., Xu, S., Tan, S., et al. (2023) · Cancer Biomarkers · doi:10.3233/cbm-220451 · Cited by 3
Shimura, Y., Shibayama, H., Nakaya, A., Yamamura, R., Imada, K., Kaneko, H., Hanamoto, H., Fuchida, S., Tanaka, H., Kosugi, S., et al. (2023) · International Journal of Hematology · doi:10.1007/s12185-023-03653-4 · Cited by 3
“Recently, several new drugs, including monoclonal antibodies for cell surface antigen, have been approved for the therapy of patients with transplant-ineligible NDMM [8, 9].”
BackgroundLoponen, H., Mehtälä, J., Ylisaukko‐oja, T., et al. (2023) · eJHaem · doi:10.1002/jha2.802 · Cited by 3
Tso, A. C. Y., Wang, S. S. Y., Gallardo, C. A., et al. (2024) · Clinical Hematology International · doi:10.46989/001c.92085 · Cited by 3
A Rare Case of Daratumumab-Associated Encephalopathy in Multiple Myeloma
Xiang, J., Hong, Z., Zhang, Y., Chen, J., Shen, J., & Zhu, N. (2024) · Immunotherapy · doi:10.2217/imt-2023-0321 · Cited by 3
Matsunaga, N., Suzuki, T., Nishitarumizu, N., Nakanishi, Y., Kondo, A., Kato, Y., Ebina, T., Marumo, Y., Nakamura, T., Nakashima, T., et al. (2024) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2024.03.012 · Cited by 3
Sakashita, M., Sahara, N., Aoki, J., Matsunaga, T., Kobayashi, S., Kitahara, S., Fujii, T., & Ohno, N. (2024) · Oncology Letters · doi:10.3892/ol.2024.14381 · Cited by 3
Shimazu, Y., Kanda, J., Onda, Y., Fuchida, S., Ohta, K., Shimura, Y., Kosugi, S., Yamamura, R., Matsuda, M., Hanamoto, H., et al. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03711-8 · Cited by 3
Mele, G., Derudas, D., Conticello, C., Barilà, G., Gentile, M., Rocco, S., Palmieri, S., Palazzo, G., Germano, C., Reddiconto, G., et al. (2024) · Annals of Hematology · doi:10.1007/s00277-024-05811-y · Cited by 3
“The CASTOR [31] and POLLUX phase 3 trials [32] showed that the addition of daratumumab to bortezomib plus dexamethasone (HR 0.41; 95% CI, 0.21–0.83) or to lenalidomide documented even in the absence of local aggressive radiotherapy and in transplant-ineligible patients, thus suggesting that…”
InfluentialAlrasheed, M. A., Alamer, K. A., Albishi, M., Alsuhibani, A. A., Almohammed, O. A., Alwhaibi, A. M., Almajed, A. N., & Guo, J. J. (2024) · Pharmaceuticals · doi:10.3390/ph17070815 · Cited by 3
“It is also being investigated for the treatment of other types of cancer, such as light chain amyloidosis [8,9,19–22] Ixazomib (Ninlaro) is an orally administered proteasome inhibitor, a multiprotein complex that is essential for cellular protein turnover.”
BackgroundMai, E. K., Nogai, A., Lokhorst, H. M., van der Holt, B., Zweegman, S., Weisel, K. C., Croockewit, S., Jauch, A. S., Hillengaß, J., Stevens‐Kroef, M., et al. (2024) · HemaSphere · doi:10.1002/hem3.70052 · Cited by 3
Self-citationInfusion von Daratumumab in Kombinationstherapien – Praktische Hinweise für den ambulanten Bereich
Scheid, C., Munder, M., Salwender, H. J., & Engelhardt, M. M. (2018) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-0595-5397 · Cited by 3
“Zwar traten Neutropenie sowie IRR häufiger auf, allerdings führte die Zunahme der Nebenwirkungen (z. B. IRR) nicht zu höheren Therapieabbruchraten oder häufigeren Todesfällen [3].”
BackgroundInfluentialBay, J., André, T., Caux, C., Évrard, S., Gonçalves, A., L’Allemain, G., Magné, N., Orbach, D. H., Penel, N., Rodrigues, M. J., et al. (2019) · Bulletin du Cancer · doi:10.1016/j.bulcan.2018.12.005 · Cited by 3
Resistance Mechanisms to Novel Therapies in Myeloma
Wallington-Beddoe, C. T., & Coghlan, D. W. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.77004 · Cited by 3
“High cell surface expression occurs on benign and malignant plasma cells [111] with the fully-humanised anti-CD38 mAb Daratumumab demonstrating impressive outcomes when combined with Bortezomib (CASTOR) or Lenalidomide (POLLUX) in the relapsed/refractory MM setting [112, 113].”
BackgroundEvolution of Therapy for Relapsed/Refractory Multiple Myeloma
Castillo, J. J. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.5035 · Cited by 3
Anticorps anti-CD38 dans le myélome multiple
Moreaux, J. (2019) · médecine/sciences · doi:10.1051/medsci/2019198 · Cited by 3
Horisawa, Y., Kondo, T., Hishizawa, M., et al. (2020) · Annals of Hematology · doi:10.1007/s00277-020-04029-y · Cited by 3
Oriol, A., Ibarra, G., Abella, E., Motlló, C., Cibeira, M. T., García, A., Escoda, L., Granell, M., Azaiz, R. B., Cervera, M., et al. (2020) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2020.1817439 · Cited by 3
“After relapse, current standards are triplet combinations maintained up to the next progression [11,12,27].”
BackgroundSelf-citationMexican Consensus of Multiple Myeloma
de la Peña-Celaya, J. A., Aguilar-Luévano, J., Alcivar-Cedeño, L. M., Álvarez-Vera, J. L., Anaya-Cuéllar, I., Añorve-Hernández, É., Arana-Luna, L. L., Arteaga-Ortíz, L., Baez-Islas, P. E., Banda-García, L. I., et al. (2020) · Gaceta Médica de México · doi:10.24875/gmm.m20000392 · Cited by 4
Chari, A., Munder, M., Weisel, K. C., Jenner, M. W., Bygrave, C., Petrucci, M. T., Boccadoro, M., Cavo, M., van de Donk, N. W. C. J., Turgut, M., et al. (2021) · Advances in Therapy · doi:10.1007/s12325-020-01601-w · Cited by 3
Self-citationAttardi, E., Pilerci, S., Attucci, I., Buzzichelli, A., Messeri, M., Staderini, M., Vannucchi, A. M., & Antonioli, E. (2021) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2021.06.018 · Cited by 3
Isatuximab, Carfilzomib and Dexamethasone (Isa-Kd) for the Management of Relapsed Multiple Myeloma
Banerjee, R. K., Lo, M., & Martin, T. G. (2021) · Future Oncology · doi:10.2217/fon-2021-0778 · Cited by 3
Multiple Myeloma: Therapeutic Delivery of Antibodies and Aptamers
Pujol-Navarro, N., Qaraghuli, M. M. A., Kubiak-Ossowska, K., Alsaadi, M., Horne, G. A., Soutar, R. L., Paspali, E., Ferro, V. A., Williams, M. T. S., & Mulheran, P. A. (2021) · Therapeutic Delivery · doi:10.4155/tde-2021-0041 · Cited by 3
Bertuglia, G., Cani, L., Larocca, A., Gay, F., & D’Agostino, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232415879 · Cited by 3
“…analyzed daratumumab effects in combination with lenalidomide and dexamethasone (Rd) vs. lenalidomide and dexamethasone in the POLLUX trial, showing that daratumumab in combination with Rd induced deeper effects in NK cells and CD8+ activation than Rd alone, especially in deep responders [129,130].”
BackgroundDiagnostik und Therapie des Multiplen Myeloms
Baertsch, M., & Goldschmidt, H. (2017) · Info Onkologie · doi:10.1007/s15004-017-5561-7 · Cited by 3
“Carfilzomib/ Lenalidomid/ Dexamethason (ASPIRE [23]) Elotuzumab/ Lenalidomid/ Dexamethason (ELOQUENT-2 [22]) Ixazomib/ Lenalidomid/ Dexamethason (TOURMALINE [24]) Daratumumab/ Lenalidomid/ Dexamethason (POLLUX [21]) Panobinostat/ Bortezomib/ Dexamethason (PANORAMA-1 [25]) Daratumumab/ Bortezomib/ Dexamethason (CASTOR…”
BackgroundSelf-citationImmunotherapy Strategies Against Multiple Myeloma
Ma, J., Li, Q., Yu, Z., Cao, Z., Liu, S., Chen, L., Li, H., Gao, S., Yan, T., Wang, Y., et al. (2017) · Technology in Cancer Research & Treatment · doi:10.1177/1533034617743155 · Cited by 3
Krzywdzińska, A., Solarska, I., Puła, B., et al. (2018) · Hematologia · doi:10.5603/hem.2017.0035 · Cited by 3
“pl/hematologia w leczeniu i uzyskiwanie trwałych i głębokich odpowiedzi [1, 14].”
BackgroundGiralt, S., & SEIFTER, E. J. (2018) · Hematology · doi:10.1182/asheducation-2018.1.103 · Cited by 3
“K’s case, based on the CASTOR and POLLUX data, I would propose a daratumumab-containing regimen (either daratumumab, bortezomib, and dexamethasone or daratumumab, lenalidomide, and dexamethasone).(32,33) Since she has been on lenalidomide maintenance, I would probably like to do the change in class and thus reinduce h…”
MethodManier, S., de la Contrie, M. D. C., Hieulle, J., Daniel, A., & Facon, T. T. F. (2019) · La Presse Médicale · doi:10.1016/j.lpm.2019.07.023 · Cited by 3
Sugiura, I., Suzuki, K., Ri, M., et al. (2019) · International Journal of Hematology · doi:10.1007/s12185-019-02754-3 · Cited by 3
Self-citationDaratumumab therapy for relapsed or refractory multiple myeloma: a single-center retrospective study
Sunami, K., Murakami, H., Tagashira, H., Ueda, H., Moriyama, T., Ishikawa, T., Yoshioka, T., & Makita, M. (2020) · International Journal of Clinical Oncology · doi:10.1007/s10147-020-01754-2 · Cited by 3
McCurdy, A. B. R., Louzada, M., Venner, C. P., et al. (2022) · eJHaem · doi:10.1002/jha2.559 · Cited by 3
“Interestingly, the uses of KRd appears to drop precipitously in 2019, which is when the combinations of daratumumab with lenalidomide and dexamethasone (per the POLLUX trial [27]) or bortezomib and dexamethasone (per theCASTOR trial [28]) becamepublicly funded andmay have been a factor resulting in decreased KRd use.”
BackgroundSelf-citationMartin, T. G., Capra, M., Mohty, M., Suzuki, K., Quach, H., Cavo, M., Moreau, P., Dimopoulos, M. A., Yong, K., Tekle, C., et al. (2022) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2022.11.005 · Cited by 3
Self-citationSpencer, A. G., Kalff, A., Shortt, J., Quach, H., Wallington-Beddoe, C. T., Reynolds, J., Walker, P., Harrison, S. J., Dunn, R. D., & Wellard, C. J. (2023) · British Journal of Haematology · doi:10.1111/bjh.18955 · Cited by 3
“Based on a Bayesian ‘proof of concept’ (PoC) approach, if two criteria were not fulfilled: (1) Observed clinical benefit rate (CBR) ≥ clinically determined threshold (of 25%) and (2) Posterior probability that the true CBR is > a futility threshold (of 20%), given the observed data, is > a specified level of proof (of…”
BackgroundMethodAlegre, A. M., de la Rubia, J., Sureda, A. M., Rodríguez, C. E., Suárez, A., Blanchard, M. J., Bargay, J., Rodríguez‐Otero, P., Insunza, A., Palomera, L., et al. (2020) · HemaSphere · doi:10.1097/hs9.0000000000000380 · Cited by 3
“The addition of daratumumab to lenalidomide and dexamethasone in the phase 3 POLLUX trial resulted in a 63% reduction in the risk of disease progression or death and an overall response rate of 93%.(14) In both studies, responses to daratumumab continued to deepen and were associated with significantly higher minimal…”
BackgroundMultiple Myeloma: Current Advances and Future Directions
Murakami, H. (2020) · The Kitakanto Medical Journal · doi:10.2974/kmj.70.175 · Cited by 3
Three Drug Combinations in the Treatment of Fit Elderly Multiple Myeloma Patients
Gardeney, H., Bobin, A., Gruchet, C., Sabirou, F., Lévy, A., Nsiala, L., Cailly, L., Tomowiak, C., Diaz, J. M. T., Moya, N., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9113554 · Cited by 4
“The phase III open label MAIA study [37], compared DRd until progression in 28 days cycles to Rd.”
MethodDaratumumab Plus Carfilzomib: An Optimistic Approach in Relapsed/ Refractory Multiple Myeloma
Dubey, A., Khatri, S., Maggo, S., et al. (2020) · Indian Journal of Medical and Paediatric Oncology · doi:10.4103/ijmpo.ijmpo_84_20 · Cited by 3
“Indian Journal of Medical and Paediatric Oncology | Volume 41 | Issue 6 | November-December 2020 847 in combination with other standard therapy has significantly resulted in reduced disease progression or death by inducing rapid, deep, and durable responses in patients of RRMM.[3-5] However, majority of these trials e…”
ResultInfluentialInsuffisance rénale dans le myélome multiple : particularités de la prise en charge
Try, M., & Harel, S. (2023) · Bulletin du Cancer · doi:10.1016/j.bulcan.2022.12.015 · Cited by 2
Karp, S., Trautmann‐Grill, K., Warncke, P., Zolnowski, D., Röllig, C., Pannach, M., Zinn, J., Kroschinsky, F., Morgner, A., Bonin, M. V., et al. (2025) · Annals of Hematology · doi:10.1007/s00277-025-06262-9 · Cited by 2
“…Immunoglobulin; IMiD: immunomodulatory drug; LC: light chain; PI: proteasome inhibitor; PR: partial remission; R-ISS: Revised International Staging System; VGPR: very good partial remission anti-CD38 mAb (daratumumab, isatuximab) are regularly used and have shown convincing data [5–8, 10, 34–46].”
Kulig, P., Rałowiec, A., Baumert, B., & Machaliński, B. (2025) · Clinical and Experimental Medicine · doi:10.1007/s10238-025-01728-6 · Cited by 2
“Another new class of drugs are monoclonal antibodies, for example daratumumab, which is directed against CD38 [20].”
Suichi, T., Misawa, S., Shibuya, K., Morooka, M., Ogushi, M., Oshima‐Hasegawa, N., Tsukamoto, S., Takeda, Y., Mimura, N., Sakaida, E., et al. (2025) · Hematology · doi:10.1080/16078454.2025.2519896 · Cited by 2
Revolutions at the frontline of multiple myeloma treatment: lessons and challenges to finding a cure
Kort, J., Rivera, A., Senigarapu, S., & Driscoll, J. J. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1578529 · Cited by 2
Rizzello, I., Sacchetti, I., Barbato, S., Solli, V., Stefanoni, P., Cani, L., Quaresima, M., Belotti, A., Sgherza, N., Gentile, M., et al. (2025) · Clinical and Experimental Medicine · doi:10.1007/s10238-025-01956-w · Cited by 2
Mina, R., Antonioli, E., Barilà, G., Bolli, N., Botta, C., Furlan, A., Liberatore, C., Martello, M., Móre, S. M. C., Oliva, S., et al. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.12.016 · Cited by 3
Huang, Z.-Y., Liu, X.-L., Li, T., & Luo, C.-H. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2025.1729177 · Cited by 3
Roy, P. G., Gogia, A., Anwar, Z., Mukherjee, S., & Anwer, F. (2026) · JCO Oncology Practice · doi:10.1200/op-25-00947 · Cited by 2
The use of DTT in the resolution of the interferences generated by daratumumab in the blood bank
Barrientos-Soto, M. C., Castañeda-García, M., Herrera-García, A., et al. (2017) · Medicina Universitaria · doi:10.1016/j.rmu.2017.07.006 · Cited by 2
The first relapse in multiple myeloma: how to pick the next best thing
Devarakonda, S. S., Sharma, N., & Efebera, Y. A. (2022) · Hematology · doi:10.1182/hematology.2022000356 · Cited by 2
Ríos, R., Soler, A., García‐Sánchez, R., Persona, E. P., Arnao, M., García‐Guiñón, A., Domingo, A., González-Pardo, M., de la Rubia, J., Mateos, M., et al. (2023) · Hematology · doi:10.1080/16078454.2023.2178997 · Cited by 2
“…RCTs and this RW practice study may be partly attributed to the baseline clinical and demographic characteristics of the patients enrolled in our study, such as an older median age (range 6 – 10 years older [7,11,12,24,28]) and the presence of comorbidities, including cardiac and renal failure.”
BackgroundResultInfluentialExpert Council Review “Multiple myeloma”
Akhmedov, M., & Zeynalova, P. A. (2023) · Oncohematology · doi:10.17650/1818-8346-2023-18-2-10-16 · Cited by 3
Fu, X.-H., Guan, R.-Y., Huang, Z., Li, Y., Lu, G., Mou, W.-W., & Du, J. (2023) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/1574892818666230619093300 · Cited by 2
Clinical Outcomes of Patients with Multiple Myeloma after Daratumumab Failure
Zamanillo, I., de Alba, L. M., Gil, R., de la Puerta, R., Alonso, R., Ubieto, A. J., Cedena, M., Calbacho, M., Ayala, R. M., & Martínez‐López, J. (2023) · Life · doi:10.3390/life13091841 · Cited by 2
“They have demonstrated efficacy both as single agents [3,4] and in combination with other anti-myeloma drugs [5–7], which has led to their approval by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of multiple myeloma (MM), as a first-line therapy and…”
Ryabukhina, Y. E., Zeynalova, P. A., Тимофеева, О. Л., Abbasbeyli, F. M., Valiev, T. T., & Александровна, К. Н. (2023) · MD-Onco · doi:10.17650/2782-3202-2023-3-3-48-56 · Cited by 2
An atypical presentation of visceral leishmaniasis mimicking multiple myeloma relapse
Benevolo, G., Bertuglia, G., Bringhen, S., et al. (2023) · American Journal of Hematology · doi:10.1002/ajh.27147 · Cited by 2
Hämatologische Neoplasien und solide Tumore
Ludwig, W.-D., Ganser, A., & Maschmeyer, G. (2023) · Springer eBooks · doi:10.1007/978-3-662-68371-2_5 · Cited by 2
Hernandez-Lopez, P., Vijaykumar, T., Anand, P., Auclair, D., Frede, J., Knoechel, B., & Lohr, J. G. (2024) · Blood Advances · doi:10.1182/bloodadvances.2023011463 · Cited by 1
The Role of Monoclonal Antibodies in the Treatment of Myeloma Kidney Disease
Derudas, D., & Chiriu, S. (2024) · Pharmaceuticals · doi:10.3390/ph17081029 · Cited by 3
A case of refractory IgG4-related disease successfully treated with daratumumab and lenalidomide
Coulomb, D., Szablewski, V., Robert, N., et al. (2024) · Lara D. Veeken · doi:10.1093/rheumatology/keae448 · Cited by 2
Flow Cytometric MRD Detection in Selected Mature B-Cell Malignancies
Engelmann, R., & Böttcher, S. (2024) · Methods in molecular biology · doi:10.1007/978-1-0716-4188-0_7 · Cited by 2
Visualizing immunotherapy for multiple myeloma worldwide from 2013 to 2023: A bibliometric analysis
Li, J., Li, X., Fu, Y., Meng, H., Xu, D., & Hou, W. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2433304 · Cited by 2
Relative Dose Intensity of Daratumumab, Lenalidomide, and Dexamethasone in Multiple Myeloma
Suzuki, K., Gunji, T., Kawashima, M., et al. (2025) · Cancers · doi:10.3390/cancers17030470 · Cited by 2
“The RDI was calculated by dividing the total dose by the estimated dose according to the MAIA and POLLUX trials [4,6].”
Self-citationWu, W., Wang, Y., Lou, Y., Fan, X., Yang, W., Tang, F., Zhao, Z., & Dong, H. (2025) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2025.2461636 · Cited by 3
“The PFS Kaplan-Meier curves for DVd, DRd, and Kd were derived from the studies of CASTOR [26], POLLUX [27], and ENDEAVOR [28], respectively, and were fitted with the Weibull distribution for DVd and Kd, and with the log-normal distribution for DRd.”
InfluentialSuzuki, K., Gunji, T., Nagao, R., et al. (2025) · International Journal of Hematology · doi:10.1007/s12185-025-03941-1 · Cited by 2
Self-citationXie, D., & Zhang, P.-F. (2025) · BMJ Open · doi:10.1136/bmjopen-2023-076914 · Cited by 2
Abuhelwa, A. Y., Almansour, S. A., Basch, E., Al-Shamsi, H. O., Abuhelwa, Z., Bustanji, Y. K., Semreen, M. H., Kharaba, Z. J., Ali, S. M., Mohamed, R., et al. (2025) · European Journal Of Haematology · doi:10.1111/ejh.14410 · Cited by 2
“Individual patient data from three open-label, randomized trials were pooled for this analysis: MAIA (NCT02252172, data cut-off: February 19, 2021) [21], POLLUX (NCT02076009, data cut-off: March 7, 2016) [22], and CASTOR (NCT02136134, data cut-off: January 11, 2016) [23].”
Zilu, M., Zheng, H., Li, Y., Bai, J., Zhang, L., & Li, L. (2025) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2025.101202 · Cited by 2
Minařík, J., Pour, L., Látal, V., et al. (2025) · BMC Cancer · doi:10.1186/s12885-025-14087-y · Cited by 2
Relapsed/refractory multiple myeloma: standard of care management of patients in the Gulf region
Alhuraiji, A., Farsi, K. A., Mheidly, K., Elsabah, H., Cherif, H., Hamad, A. A., Marashi, M., Al-Hateeti, H., Osman, H. Y., & Mohty, M. (2025) · Clinical Hematology International · doi:10.46989/001c.137860 · Cited by 2
Kim, D. Y., Min, C., Eom, H., et al. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.06.006 · Cited by 2
Ntanasis‐Stathopoulos, I., Malandrakis, P., Filippatos, C., Maganas, S., Fotiou, D., Theodorakakou, F., Spiliopoulou, V., Kanellias, N., Migkou, M., Eleutherakis‐Papaiakovou, E., et al. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.08.003 · Cited by 2
Self-citationTrends in survival for adult patients with hematopoietic malignancies in Japan, 2000–14 (CONCORD-3)
Yoshida, I., Carlo, V. D., Matz, M., Yamashita, N., Teramoto, N., Oki, I., Shibata, A., Nakata, K., Saito, M. K., Matsuzaka, M., et al. (2025) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyaf145 · Cited by 2
Integrating Emerging Data Into Clinical Practice: A Case-Based Approach for Multiple Myeloma
Sandra Kurtin, P. (2017) · Journal of the Advanced Practitioner in Oncology · doi:10.6004/jadpro.2017.8.4.5 · Cited by 2
“The triple-drug combination was associated with a 63% reduction in the risk of disease progression or death at 13.5 months of follow-up ( p < .0001; Dimopoulos et al., 2016).”
InfluentialThe role of elotuzumab in the treatment of relapsed or refractory multiple myeloma
Comeau, J. M., Kelly, K., & Jean, G. W. (2018) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp160554 · Cited by 2
Cherniawsky, H. M., Kukreti, V., Reece, D. E., Masih‐Khan, E., McCurdy, A. B. R., Jimenez-Zepeda, V. H., Sébag, M., Song, K., White, D. J., Stakiw, J., et al. (2021) · European Journal Of Haematology · doi:10.1111/ejh.13596 · Cited by 2
Self-citation
Metadata
- Authors
- Dimopoulos, M. A., Oriol, A., Nahi, H., San-Miguel, J., Bahlis, N. J., Usmani, S. Z., Rabin, N., Orlowski, R. Z., Komarnicki, M., Suzuki, K., Plesner, T., Yoon, S.-S., Ben Yehuda, D., Richardson, P. G., Goldschmidt, H., Reece, D., Lisby, S., Khokhar, N. Z., O’Rourke, L., Chiu, C., Qin, X., Guckert, M., Ahmadi, T., & Moreau, P.
- Affiliations
- Karolinska University Hospital (SE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-10-06
- Volume
- 375
- Issue
- 14
- Pages
- 1319-1331
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2528329272
- Cited by
- 1,445
- References
- 32
- Citations by year
- 2026: 50 · 2025: 78 · 2024: 78 · 2023: 108 · 2022: 138 · 2021: 221 · 2020: 236 · 2019: 175 · 2018: 193 · 2017: 148 · 2016: 15
- FWCI
- 168.28
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- University of Southern Denmark Research Portal (University of Southern Denmark) (submittedVersion, other-oa)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
- Funders
- Amgen
- Bristol-Myers Squibb
- Spectrum Pharmaceuticals
- Celgene
- Incyte
- Otsuka Pharmaceutical
- Chugai Pharmaceutical
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Keywords
- daratumumab, lenalidomide, dexamethasone, relapsed/refractory multiple myeloma, progression-free survival, minimal residual disease, complete response, neutropenia, thrombocytopenia, adverse events, monoclonal antibody therapy, combination therapy, overall response rate, safety and tolerability
- MeSH terms
- Lenalidomide, Aged, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Dexamethasone, Humans, Middle Aged, Multiple Myeloma, Recurrence, Thalidomide, Disease-Free Survival, Drug Resistance, Neoplasm, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
